Incyte INCY Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Product | ||||||
| ICLUSIG | $35.46M+20.0% | $34.22M+25.0% | $37.58M+26.3% | $32.73M+21.8% | $29.54M-2.6% | |
| JAKAFI | $757.76M+6.8% | $828.24M+7.1% | $791.07M+6.7% | $763.79M+8.2% | $709.41M+24.1% | |
| JAKAVI Royalty Revenues | $105.56M+14.6% | $130.23M+14.0% | $125.65M+8.6% | $109.71M+10.5% | $92.15M+2.8% | |
| Milestone and contract revenues | $17M— | $100M— | $45M+150% | $5M— | $0-100% | |
| MINJUVI/MONJUVI | $49.23M+66.6% | $41.91M+27.7% | $41.99M+33.6% | $31.13M0.0% | $29.55M+23.8% | |
| NIKTIMVO | $55.09M+305% | $56.04M— | $45.83M— | $36.15M— | $13.61M— | |
| OLUMIANT Royalty Revenues | $36.41M+18.2% | —— | $37.11M+6.7% | $33.48M+5.6% | $30.8M+0.7% | |
| OPZELURA | $143.02M+20.5% | $207.28M+28.3% | $187.97M+35.0% | $164.5M+35.2% | $118.71M+38.5% | |
| Other product royalty revenues | $3.25M+156% | $3.47M+942% | $1.86M+348% | $1.29M+46.9% | $1.27M+131% | |
| PEMAZYRE | $22.54M+22.3% | $23.35M+0.9% | $22.74M+10.1% | $22.19M+9.5% | $18.44M+4.3% | |
| TABRECTA Royalty Revenues | $5.98M-6.7% | $7.14M+13.6% | $6.51M+9.9% | $6.63M+25.2% | $6.41M+22.5% | |
| ZYNYZ | $41.39M+1,276% | $31.75M+2,212% | $22.67M+3,167% | $8.92M+1,270% | $3.01M+544% | |
| Accrued and other liabilities by Product | ||||||
| Axatilimab - Commercialization Activities | $22.5M— | $27.6M— | —— | —— | —— | |
| Axatilimab - Development Activities | $1.4M— | $2.4M+9.1% | —— | —— | —— | |
| Total revenues by Geography | ||||||
| Europe | $92.43M+34.7% | $75.99M-14.5% | $100.31M+50.9% | $78.83M+47.1% | $68.61M+33.2% | |
| Other countries | $8.78M+222% | $6.08M+142% | $4.41M+223% | $4.35M+280% | $2.73M+127% | |
| United States | $1.17B+19.3% | $1.42B+31.0% | $1.26B+17.9% | $1.13B+14.5% | $981.56M+18.5% | |
| PP&E (Net) by Geography | ||||||
| Other countries | $14.01M+7.8% | $14.25M+21.9% | $13.47M— | $13.95M— | $13M— | |
| Switzerland | $304.82M+7.8% | $309.8M+11.6% | $308.11M— | $310.21M— | $282.7M— | |
| United States | $401.34M-14.5% | $406.83M-14.2% | $477.06M— | $474.38M— | $469.6M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Incyte break its business down?
- Incyte (INCY) reports total revenues by product across 12 parts — ICLUSIG, JAKAFI, JAKAVI Royalty Revenues, Milestone and contract revenues and MINJUVI/MONJUVI. Each is extracted from the segment footnotes and tracked over time.
- Where does Incyte's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Incyte's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
